Overview
Goals and Objectives
Our Team
Lines of Research
Publications
Group Collaborators
Biomarkers are biomolecules that are associated with or inform about physiological processes, diseases, and so on. There is an urgent need to identify novel biomarkers that are first and foremost informative about a specific disease (or a set of diseases) and the majority of them are applicable to the target population. Proteomics and metabolomics methodologies are now the foundation of fundamental and translational biomedical research all over the world. The use of proteomics and metabolomics in the search for disease biomarkers, on the other hand, will continue to advance drug development and personalized therapy in the future. A panel of novel protein/metabolite sensitive biomarkers will undoubtedly be a valuable bio-molecular resource for effectively monitoring drug treatment and accurately assessing the efficacy of new drugs/therapies (including the nature inspired compound library available at the Sharjah Institute for Medical Research (SIMR)).
- The main goal of this group is to thoroughly identify proteins/metabolites that result from alterations in biological processes associated with non-communicable diseases but also against important infectious diseases such as COVID-19
- Contribute to a better understanding of the underlying mechanisms of diseases through the application of large-scale proteomics and metabolomics.
- Optimization of large-scale data analysis and downstream computational, bioinformatics analysis and machine learning.
- Consistently verification and translational of identified disease biomarkers through the application of MS-based quantitative measurements.
- Developed qualified biomarkers warranty approved by the FDA
- Identify new targets for drugs against non-communicable diseases but also against important infectious diseases such as COVID-19
- Utilize qualified biomarker(s) to develop and test therapeutic agents against Human diseases
- Development of immunochemistry/colorimetric products for a rapid detection of the qualified biomarkers
- Cancer Biomarkers -early diagnosis and treatment follow up
- Novel biomarkers for early detection of Diabetes in the Emirati population
- Biomarkers of Infectious diseases -Covid-19, Tuberculosis and Candida
- Search for biomarkers of neuropathological disorders and treatment follow up
Research Publications
No Record Found
Prof. Christoph Borchers1,2,3
(1) Skolkovo Institute of Science and Technology (Skoltech), Center for Computational and Data-Intensive Science and Engineering/Laboratory of Omics Technologies and Big Data for Personalized Medicine and Health.(2) Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
(3) Gerald Bronfman Department of Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Prof Jose Luis Capelo1,2
New University of Lisbon(1) Bioscope Group, LAQV@ Requimte, Chemistry Department, Faculty of Science and Technology, NOVA University of Lisbon, 2825-466 Almada Portugal
(2) Proteomass Scientific Society, 2825-466 Costa de Caparica, Portugal.
Prof. Luis Zerbini
Cancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa. luiz.zerbini@icgeb.orgDr. Stefano Cacciatore1,2
(1) Cancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa
(2) Institute for Reproductive and Developmental Biology, Imperial College, London, UK.
Prof. Jonathan M Blackburn1,2
(1) Division of Chemical & Systems Biology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town. South Africa(2) Institute of Infectious Disease & Molecular Medicine, Faculty of Health Sciences, University of Cape Town. South Africa